Companies › Shenzhen Shenxin Biotechnology
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) Bivalent mRNA vaccine targeting respiratory syncytial virus | RSV | Phase 2 | Respiratory Syncytial Virus (RSV) Infection; Respiratory Syncytial Virus Infections | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06645665 | Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) | Phase 1 | Respiratory Syncytial Virus Infections | Infectious disease | Apr 2027 |
| NCT07128121 | Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006) | Phase 2 | Respiratory Syncytial Virus (RSV) Infection | Infectious disease | Oct 2029 |
Sanofi ModernaTX AstraZeneca MAXVAX Biotechnology Limited Liability Company Enanta Pharmaceuticals GSK
Biothervax OsteoRemedies Jiangsu ProteLight Pharmaceutical & Biotechnology MAXVAX Biotechnology Limited Liability Company Catalysis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.